Company Willow Biosciences Inc Canadian Securities Exchange
Equities
CA97111B1076
Pharmaceuticals
Business Summary
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research and Development
100.0
%
| 1 | 77.2 % | 1 | 100.0 % | +84.86% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 77.2 % | 1 | 100.0 % | +84.86% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 19-04-11 |
Travis Doupe
DFI | Director of Finance/CFO | - | 19-04-11 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 19-03-31 |
Simon Hickling
PRN | Corporate Officer/Principal | - | - |
Sony Gill
SEC | Corporate Secretary | 48 | 19-04-11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 23-02-20 |
Donald Archibald
BRD | Director/Board Member | 63 | 19-04-11 |
Director/Board Member | 51 | 19-04-11 | |
Raffi Asadorian
BRD | Director/Board Member | 54 | 23-05-10 |
Chris Savile
CEO | Chief Executive Officer | - | 19-04-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 126,950,810 | 92,241,495 ( 72.66 %) | 0 | 72.66 % |
Company contact information
Willow Biosciences, Inc.
1201 5th Street South West Suite 202
T2R 0Y6, Calgary
+
http://www.willowbio.comSector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |